Scleroderma clinical trials

Explore recruiting scleroderma clinical trials.

Recruiting scleroderma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Scleroderma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Mesenchymal stem cells for Angiogenesis and Neovascularisation in digital Ulcers of Systemic sclerosis: the MANUS Trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy and safety of allogenic cultured Adipose-derived mesenchymal stromal cell injections on MoUth fibrosis and handicap in patients with Systemic sclEroderma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic sclerosis MSC-AT-SSc

France

Therapeutic exploratory (Phase II) EU CTIS Study details

CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis

Poland, Germany, Spain, Norway, Netherlands, Denmark +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Scleroderma trials by city

Scleroderma in Toronto Scleroderma in Vancouver Scleroderma in Montreal Scleroderma in Calgary Scleroderma in Edmonton Scleroderma in Ottawa Scleroderma in Winnipeg Scleroderma in Quebec City Scleroderma in Hamilton Scleroderma in Kitchener Scleroderma in London Scleroderma in Halifax Scleroderma in New York Scleroderma in Los Angeles Scleroderma in Chicago Scleroderma in Houston

Other conditions

Celiac disease GERD Eosinophilic esophagitis Gastroparesis Rheumatoid arthritis Lupus Psoriatic arthritis Ankylosing spondylitis Osteoarthritis Knee osteoarthritis Osteoporosis Sjogren's syndrome Fibromyalgia Psoriasis Eczema (atopic dermatitis) Acne Vitiligo Hidradenitis suppurativa Rosacea Alopecia areata Endometriosis Uterine fibroids Menopause Infertility